AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 83 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $37,000 | -82.0% | 3,575 | -71.3% | 0.00% | – |
Q2 2023 | $205,000 | – | 12,460 | +6130.0% | 0.00% | – |
Q2 2022 | $0 | -100.0% | 200 | -70.0% | 0.00% | – |
Q1 2022 | $4,000 | -42.9% | 667 | -10.3% | 0.00% | – |
Q4 2021 | $7,000 | -30.0% | 744 | -20.7% | 0.00% | – |
Q3 2021 | $10,000 | +400.0% | 938 | +122.8% | 0.00% | – |
Q2 2021 | $2,000 | -60.0% | 421 | -18.4% | 0.00% | – |
Q1 2021 | $5,000 | -16.7% | 516 | -40.6% | 0.00% | – |
Q4 2020 | $6,000 | +500.0% | 869 | -13.1% | 0.00% | – |
Q1 2019 | $1,000 | 0.0% | 1,000 | +300.0% | 0.00% | – |
Q4 2018 | $1,000 | -95.5% | 250 | -95.0% | 0.00% | – |
Q3 2018 | $22,000 | -35.3% | 5,000 | -9.6% | 0.00% | – |
Q2 2018 | $34,000 | -41.4% | 5,532 | -31.2% | 0.00% | – |
Q1 2018 | $58,000 | +18.4% | 8,038 | +33.3% | 0.00% | – |
Q4 2017 | $49,000 | -23.4% | 6,029 | +0.5% | 0.00% | – |
Q3 2017 | $64,000 | -3.0% | 6,000 | 0.0% | 0.00% | – |
Q2 2017 | $66,000 | +13.8% | 6,000 | -1.3% | 0.00% | – |
Q1 2017 | $58,000 | – | 6,077 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |